Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03314181




Registration number
NCT03314181
Ethics application status
Date submitted
11/10/2017
Date registered
19/10/2017
Date last updated
16/02/2023

Titles & IDs
Public title
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
Scientific title
A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
Secondary ID [1] 0 0
2017-002099-26
Secondary ID [2] 0 0
M15-654
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Daratumumab
Treatment: Drugs - Venetoclax
Treatment: Drugs - Bortezomib

Experimental: Arm A, Part 1a: VenDd Dose Escalation - Venetoclax (Ven) various doses administered orally, once daily (QD) in combination with daratumumab (D) (1800 mg subcutaneous injection (preferred) or 16 mg/kg intravenous [IV]) administered in accordance with prescribing information and dexamethasone (d) (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).

Experimental: Arm B, Part 1b: VenDd Dose Expansion - Venetoclax at a dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).

Experimental: Arm D, Part 2a: VenDVd Dose Escalation - Venetoclax at various doses administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection [preferred] or IV) Cycles 1-8, Days 1, 4, 8 and 11), and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.

Experimental: Arm E, Part 2b: VenDVd Dose Expansion - Venetoclax at dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8, Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.

Experimental: Arm F: VenDd Dose Expansion - Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).

Experimental: Arm G: VenDd Dose Expansion - Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).

Active Comparator: Arm H: DVd Dose - Daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8: Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg on Cycles 1 - 3: Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) on Cycles 4-8: Days 1,2,4,5,8,9,11 and 12; 20 mg monthly for Cycles 9+: Day 1


Treatment: Drugs: Dexamethasone
Infusion; Intravenous (IV), or Tablet; Oral

Treatment: Drugs: Daratumumab
Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)

Treatment: Drugs: Venetoclax
Tablet; Oral

Treatment: Drugs: Bortezomib
Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Response Rate (ORR)
Timepoint [1] 0 0
Up to approximately 3.5 years after the last participant is enrolled
Primary outcome [2] 0 0
Very Good Partial Response or Better Response Rate (VGPR)
Timepoint [2] 0 0
Up to approximately 3.5 years after the last participant is enrolled
Primary outcome [3] 0 0
Complete Response (CR) or Better Rate
Timepoint [3] 0 0
Up to approximately 3.5 years after the last participant is enrolled
Primary outcome [4] 0 0
Time to Response (TTR)
Timepoint [4] 0 0
Up to approximately 3.5 years after the last participant is enrolled
Primary outcome [5] 0 0
Duration of Response (DOR)
Timepoint [5] 0 0
Up to approximately 3.5 years after the last participant is enrolled
Primary outcome [6] 0 0
Time to Progression (TTP)
Timepoint [6] 0 0
Up to approximately 3.5 years after the last participant is enrolled
Primary outcome [7] 0 0
Progression-Free Survival (PFS)
Timepoint [7] 0 0
Up to approximately 3.5 years after the last participant is enrolled
Primary outcome [8] 0 0
Overall Survival (OS)
Timepoint [8] 0 0
Up to approximately 3.5 years after the last participant is enrolled
Secondary outcome [1] 0 0
Minimal Residual Disease (MRD)
Timepoint [1] 0 0
Up to 12 months after confirmation of Complete Response (CR) or Stringent Complete Response (sCR)
Secondary outcome [2] 0 0
Cmax of Venetoclax
Timepoint [2] 0 0
Up to approximately 1 year
Secondary outcome [3] 0 0
Tmax of Venetoclax
Timepoint [3] 0 0
Up to approximately 1 year
Secondary outcome [4] 0 0
AUC0-24 of Venetoclax
Timepoint [4] 0 0
Up to approximately 1 year

Eligibility
Key inclusion criteria
- Eastern Cooperative Oncology Group (ECOG) performance status <= 2.

- Participant has relapsed or refractory multiple myeloma with documented evidence of
progression that occurred during or after the participant's last treatment regimen
based on investigator's determination of International Myeloma Working Group (IMWG)
criteria.

- Measurable disease confirmed by central lab at Screening, defined by at least 1 of the
following: Serum M-protein >= 1.0 g/dL (>= 10 g/L), OR Urine M-protein >= 200 mg/24
hours, OR Serum free light chain (FLC) >= 10 mg/dL, provided serum FLC ratio is
abnormal in participants who do not have measurable disease by Serum Protein
Electrophoresis (SPEP) or Urine Protein Electrophoresis (UPEP) criteria.

- Participant has received previous multiple myeloma treatment as defined in the
protocol.

- Bone marrow aspirate samples have been collected.

- To qualify for Part 1 and 3, the participant must be t(11;14) positive as determined
by an analytically validated Fluorescent In Situ Hybridization (FISH) assay per
central laboratory testing.

- Participants must have adequate hematologic, renal and hepatic function.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Previous treatment with venetoclax or other B-Cell Lymphoma 2 (BCL-2) inhibitor

- For participants in Parts 1 and 2: Previous treatment with daratumumab or other
anti-CD38 therapy. For participants in Part 3: Prior daratumumab or other anti-CD38
antibody therapy exposure that meets ANY of the following criteria:

- Failure to achieve at least a PR to most recent therapy with daratumumab or other
anti-CD38 therapy.

- Daratumumab or other anti-CD38 antibody therapy was discontinued due to toxicity.

- Relapse within 60 days of intensive treatment (at least every other week) of
daratumumab or other anti-CD38 antibody therapy.

- Prior treatment with daratumumab or other anti-CD38 antibody within 6 months
prior to first dose of study drug.

- For participants in Part 2 and 3:

- Participant is refractory to any proteasome inhibitor, defined as progression on
or within 60 days of the last dose of a proteasome inhibitor-containing regimen.

- Participant has had prior treatment with proteasome inhibitor within 60 days
prior to first dose of study drug.

- Treatment with anti-myeloma chemotherapy, radiotherapy, biological, immunotherapy or
an investigational therapy, including targeted small molecule agents within 2 weeks or
5 half-lives (whichever is longer and/or applicable) before first dose.

- Treatment with anti-myeloma monoclonal antibodies within 6 weeks prior to first dose.

- Recent corticosteroid therapy at a cumulative dose equivalent to >= 140 mg of
prednisone, cumulative dose equivalent to >= 40 mg of dexamethasone, or a single dose
equivalent to >= 40 mg of dexamethasone within 2 weeks prior the first dose of study
drug.

- Known central nervous system involvement of multiple myeloma.

- Significant history of medical conditions as listed in the protocol.

- History of other active malignancies including myelodysplatic syndromes (MDS) within
the past 3 years with the exceptions of:

- Basal cell carcinoma of the skin or localized squamous cell carcinoma of the
skin.

- Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific
Antigen (PSA) levels off treatment

- Previous malignancy with no evidence of disease confirmed and surgically resected
(or treated with other modalities) with curative intent and unlikely to impact
survival during the duration of the study.

- Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

- Has a hypersensitivity or allergy to any of the components of study therapy, excipient
or boron.

- Known allergies, hypersensitivities, or intolerance to monoclonal antibodies or human
proteins, or their excipients, or known sensitivity to mammalian-derived products (see
daratumumab prescribing information).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/04/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
28/08/2025
Actual
Sample size
Target
Accrual to date
Final
156
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
The Kinghorn Cancer Centre /ID# 165431 - Darlinghurst
Recruitment hospital [2] 0 0
St George Hospital /ID# 171063 - Kogarah
Recruitment hospital [3] 0 0
Royal Adelaide Hospital /ID# 171060 - Adelaide
Recruitment hospital [4] 0 0
Eastern Health /ID# 165850 - Box Hill
Recruitment hospital [5] 0 0
St Vincent's Hospital Melbourne /ID# 165853 - Fitzroy Melbourne
Recruitment hospital [6] 0 0
Peter MacCallum Cancer Ctr /ID# 164742 - Melbourne
Recruitment hospital [7] 0 0
Royal Perth Hospital /ID# 224895 - Perth
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2217 - Kogarah
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
3128 - Box Hill
Recruitment postcode(s) [5] 0 0
3065 - Fitzroy Melbourne
Recruitment postcode(s) [6] 0 0
3000 - Melbourne
Recruitment postcode(s) [7] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Colorado
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
New Jersey
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Oregon
Country [10] 0 0
United States of America
State/province [10] 0 0
Washington
Country [11] 0 0
Canada
State/province [11] 0 0
Alberta
Country [12] 0 0
Canada
State/province [12] 0 0
Quebec
Country [13] 0 0
Denmark
State/province [13] 0 0
Hovedstaden
Country [14] 0 0
Denmark
State/province [14] 0 0
Midtjylland
Country [15] 0 0
Denmark
State/province [15] 0 0
Syddanmark
Country [16] 0 0
France
State/province [16] 0 0
Franche-Comte
Country [17] 0 0
France
State/province [17] 0 0
Indre-et-Loire
Country [18] 0 0
France
State/province [18] 0 0
Pays-de-la-Loire
Country [19] 0 0
France
State/province [19] 0 0
Poitou-Charentes
Country [20] 0 0
France
State/province [20] 0 0
Val-de-Marne
Country [21] 0 0
France
State/province [21] 0 0
Paris
Country [22] 0 0
Germany
State/province [22] 0 0
Baden-Wuerttemberg
Country [23] 0 0
Germany
State/province [23] 0 0
Cologne
Country [24] 0 0
Japan
State/province [24] 0 0
Aichi
Country [25] 0 0
Japan
State/province [25] 0 0
Chiba
Country [26] 0 0
Japan
State/province [26] 0 0
Ehime
Country [27] 0 0
Japan
State/province [27] 0 0
Gifu

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AbbVie
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Janssen Research & Development, LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib
combination therapy to evaluate safety, tolerability, and efficacy of these combinations in
participants with relapsed or refractory multiple myeloma. The study will consist of 3
distinct parts: Part 1 includes participants with t(11;14) positive relapsed/refractory (R/R)
multiple myeloma who will receive venetoclax in combination with daratumumab and
dexamethasone (VenDd); Part 2 includes participants with R/R multiple myeloma who will
receive venetoclax in combination with daratumumab, bortezomib, and dexamethasone (VenDVd);
Part 3 includes participants with t(11;14) positive R/R multiple myeloma who will receive
venetoclax in combination with daratumumab and dexamethasone (VenDd) or daratumumab,
bortezomib, and dexamethasone (DVd).

Part 1 and Part 2 are non-randomized and will be initiated with a dose-escalation phase in
which increasing doses of venetoclax will be given with fixed doses of daratumumab and
dexamethasone (Part 1a) or with fixed doses of daratumumab, bortezomib, and dexamethasone
(Part 2a). Each dose escalation phase will be followed by a single-arm, open-label expansion
phase. Part 3 will include a randomized, open-label expansion phase with participants
receiving venetoclax in combination with daratumumab and dexamethasone (VenDd) or
daratumumab, bortezomib, and dexamethasone (DVd).
Trial website
https://clinicaltrials.gov/ct2/show/NCT03314181
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03314181